Physician profile
Mark E Hermann
NPI 1639148810
$2,651.78
in general payments reported to CMS, 2019-2025
37 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $106 · 2022: $11.77 · 2023: $553 · 2024: $440 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,565 · Education: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.03 |
| Education | $624.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $539.70 | 2023 | |
| Janssen Biotech, INC. | $329.38 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $208.66 | 2019-2025 | Opdivo, Krazati |
| Abbvie INC. | $187.44 | 2025 | |
| Novartis Pharmaceuticals Corporation | $162.80 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $141.89 | 2020-2025 | Tagrisso, Enhertu, Imfinzi |
| Genentech USA, INC. | $108.53 | 2019-2025 | Polivy, Lunsumio, Gazyva |
| Daiichi Sankyo INC. | $86.67 | 2019-2025 | Enhertu |
| Amgen INC. | $70.69 | 2019-2020 | |
| Beigene USA, INC. | $60.22 | 2024-2025 | Tevimbra |
| Merck Sharp & Dohme LLC | $57.52 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Stemline Therapeutics INC. | $56.03 | 2024-2025 | Orserdu |
| Genzyme Corporation | $55.97 | 2025 | |
| Pfizer INC. | $54.20 | 2025 | |
| Lilly USA, LLC | $51.24 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.